 |
| |
| Aug-08-18 | Upgrade |
Atlantic Equities |
Underweight → Neutral |
|
|
| Apr-17-18 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
| Apr-12-18 | Reiterated |
Citigroup |
Buy |
$78 → $70 |
|
| Mar-20-18 | Reiterated |
JP Morgan |
Overweight |
$70 → $75 |
|
| Feb-15-18 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
| Oct-30-17 | Upgrade |
SunTrust |
Hold → Buy |
|
|
| Oct-16-17 | Downgrade |
Jefferies |
Buy → Hold |
|
|
| Sep-12-17 | Downgrade |
Hilliard Lyons |
Long-term Buy → Neutral |
|
|
| Dec-19-16 | Upgrade |
Jefferies |
Hold → Buy |
|
|
| Oct-28-16 | Reiterated |
Deutsche Bank |
Hold |
$59 → $52 |
|
| Sep-09-16 | Reiterated |
Barclays |
Equal Weight |
$75 → $65 |
|
| Aug-11-16 | Downgrade |
Berenberg |
Buy → Hold |
|
|
| Aug-08-16 | Reiterated |
Deutsche Bank |
Hold |
$68 → $62 |
|
| Aug-08-16 | Downgrade |
Credit Suisse |
Outperform → Neutral |
$63 |
|
| Aug-05-16 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
| May-23-16 | Initiated |
Hilliard Lyons |
Neutral |
|
|
| Apr-29-16 | Reiterated |
UBS |
Buy |
$73 → $80 |
|
| Apr-29-16 | Reiterated |
Barclays |
Equal Weight |
$70 → $75 |
|
| Apr-06-16 | Initiated |
Societe Generale |
Sell |
$48 |
|
| Jan-22-16 | Upgrade |
Berenberg |
Hold → Buy |
|
|
|
|
| Aug-17-18 08:03AM | FDA approves Bristol-Myers' Opdivo for small cell lung cancer Reuters |
| 07:09AM | Bristol-Myers wins FDA approval for Opdivo as treatment for small cell lung cancer MarketWatch |
| 06:59AM | U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer Business Wire |
| Aug-16-18 09:37AM | The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait Benzinga |
| Aug-15-18 04:21PM | Heat Biologics Stock Is a Worthwhile, Speculative Bet InvestorPlace |
| 02:58PM | The stocks you wanted to know about today CNBC Videos |
| Aug-14-18 10:06AM | 5 Top-Ranked S&P 500 Stocks to Buy on Market Dip Zacks |
| 06:52AM | Zacks.com featured highlights include: United States Cellular, Molina Healthcare, Archer Daniels, Bristol-Myers and Callaway Golf Zacks |
| 06:02AM | Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb Motley Fool |
| Aug-13-18 08:13AM | Pick These 5 Stocks With Remarkable Relative Price Strength Zacks |
| 07:38AM | The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers Zacks |
| Aug-12-18 04:52PM | The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs Benzinga |
| Aug-10-18 05:39PM | Edited Transcript of BMY earnings conference call or presentation 26-Jul-18 2:30pm GMT Thomson Reuters StreetEvents |
| Aug-09-18 09:52AM | Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y Zacks |
| Aug-08-18 08:10AM | Report: Developing Opportunities within Cytosorbents, Nasdaq, Mastercard, Maxim Integrated Products, Bristol-Myers Squibb, and Equity Lifestyle Properties Future Expectations, Projections Moving into 2018 GlobeNewswire |
| Aug-07-18 09:50AM | Q2 Earnings Drive Pharma ETFs Higher Zacks |
| 09:30AM | BMY vs. NVO: Which Stock Is the Better Value Option? Zacks |
| Aug-06-18 09:09AM | The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis Zacks |
| Aug-03-18 11:23AM | Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval Zacks |
| Aug-02-18 02:10PM | Moody's: US drug makers face heightened pricing pressure as regulatory risks pick up steam Moody's |
| 12:50PM | Here's Why Exelixis Stock Jumped Higher Today Motley Fool |
| Aug-01-18 05:24PM | The opioid drug that addicts don't like could be approved next spring American City Business Journals |
| Jul-31-18 08:20AM | Today's Research Reports on Trending Tickers: Bristol-Myers Squibb and Allergan ACCESSWIRE |
| 06:59AM | European Commission Approves Bristol-Myers Squibbs Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection Business Wire |
| Jul-27-18 12:16PM | Merck profit beats, but Keytruda sales fail to impress Reuters |
| 11:01AM | Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock Zacks |
| 07:48AM | [$$] Merck overtakes rival on immunotherapy drug sales Financial Times |
| Jul-26-18 12:52PM | Bristol-Myers cancer ruling hits shares after strong earnings Reuters |
| 11:11AM | Bristol-Myers (BMY) Beats on Q2 Earnings, Raises Outlook Zacks |
| 10:59AM | Bristol-Myers to get negative CHMP opinion on renal cancer drugs Reuters |
| 10:30AM | Bristol-Myers profit tops Street view, raises full-year forecast Reuters |
| 09:10AM | Bristol-Myers Squibb (BMY) Surpasses Q2 Earnings and Revenue Estimates Zacks |
| 07:40AM | Bristol-Myers: 2Q Earnings Snapshot Associated Press |
| 07:36AM | Bristol-Myers shares lift on Q2 profit, revenue beats MarketWatch |
| 07:19AM | Bristol-Myers (BMY) Q2 Earnings Beat Estimates Zacks |
| 07:01AM | Bristol-Myers Drops After Cancer Drug Combo Rejected in Europe Bloomberg |
| 06:59AM | Bristol-Myers Squibb Reports Second Quarter Financial Results Business Wire |
| 06:59AM | Bristol-Myers Q2 earnings rise, full-year forecast up on strong sales Reuters |
| Jul-25-18 02:50PM | Q2 Earnings Preview For Bristol-Myers Squibb Benzinga |
| 10:27AM | Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More Zacks |
| 08:00AM | Today's Research Reports on Trending Tickers: Bristol-Myers Squibb and Eli Lilly and Company ACCESSWIRE |
| Jul-24-18 07:00AM | Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer Business Wire |
| 06:00AM | Bristol-Myers Stock May Rebound 8% Short Term Investopedia |
| Jul-23-18 10:59AM | Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings? Zacks |
| 08:30AM | Bristol-Myers Squibb Announces Departure of Chief Commercial Officer Business Wire |
| Jul-20-18 11:26AM | [$$] IFM Therapeutics Launches Subsidiary With $31 Million Series A The Wall Street Journal |
| Jul-19-18 11:51AM | Value investors Nygren's stock buys: Hilton, Gartner and ... CNBC Videos |
| 07:00AM | Bristol-Myers Squibb and Gritstone Oncology Announce Clinical Research Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors Business Wire |
| Jul-13-18 08:50AM | Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit Zacks |
| Jul-12-18 06:03PM | 3 Pharma Stocks Goldman Sachs Sees as Buys TheStreet.com |
| 09:21AM | Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer Zacks |
| Jul-11-18 03:11PM | Russian Drugmaker Granted License to Produce Celgene Copycat Fortune |
| 07:05AM | Moffitt licensing deal could provide new approach for some cancer patients American City Business Journals |
| 06:59AM | Bristol-Myers Squibbs Opdivo® (nivolumab) + Low-Dose Yervoy® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and... Business Wire |
| Jul-09-18 05:37PM | Could P&G bid for Bristol-Myers Squibb unit? American City Business Journals |
| 01:26PM | Only Immuno-Oncology Combination Therapy Approved by Health Canada as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma CNW Group |
| 07:10AM | Wired News - The European Commission Approves Expanded Indication for Bristol-Myers Squibb's Sprycel ACCESSWIRE |
| Jul-08-18 07:16PM | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga |
| Jul-06-18 07:41AM | Bristol-Myers' Sprycel Gets EC Approval for Label Expansion Zacks |
| Jul-05-18 12:03PM | Pfizer's Stock Ready for a 10% Rebound Investopedia |
| 11:46AM | Go Long Pfizer Stock Its an Easy Pill to Swallow InvestorPlace |
| 06:59AM | European Commission Approves Expanded Indication for Sprycel (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Business Wire |
| Jul-03-18 06:01AM | The 5 Biggest Blockbuster Drugs of 2024, and the Companies Poised to Profit From Them Motley Fool |
| Jun-29-18 07:54AM | Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma Business Wire |
| Jun-26-18 02:16PM | Bristol-Myers Stock May Rebound 9% Short Term Investopedia |
| 07:30AM | Wired News - FDA Accepts Bristol-Myers Squibbs Application for Opdivo Plus Low-Dose Yervoy for First-Line Non-Small Cell Lung Cancer Treatment ACCESSWIRE |
| 06:00AM | 13 Companies With Attractive, Low-Risk Dividends Morningstar |
| Jun-22-18 04:56PM | Bristol-Myers' BLA for Opdivo Label Expansion Accepted by FDA Zacks |
| 09:52AM | Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI Zacks |
| 08:51AM | Benzinga's Daily Biotech Pulse: FDA Greenlights Tandem Diabetes' Insulin Pump, More IPOs On Tap Benzinga |
| Jun-21-18 04:15PM | U.S. Food and Drug Administration (FDA) Accepts Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Non-Small Cell Lung Cancer in Patients with Tumor Mutational Burden 10 mut/Mb Business Wire |
| 08:49AM | What You Must Know About Bristol-Myers Squibb Companys (NYSE:BMY) 7.31% ROE Simply Wall St. |
| 07:28AM | Initiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug Makers Equities ACCESSWIRE |
| Jun-20-18 09:02AM | NYSE Pharma And Biotech Dividend Stock Picks Simply Wall St. |
| 06:59AM | Dallas Cowboys Quarterback Dak Prescott, Modern Family Star Eric Stonestreet and Actress Tia Mowry Call on Americans to Rise Up Against Cancer Through Ready. Raise. Rise. Business Wire |
| Jun-18-18 06:23PM | Bristol-Myers Posts Data on Empliciti, China Approves Opdivo Zacks |
| 03:00PM | Eight Stocks That Are Poised to Change Direction TheStreet.com |
| 06:00AM | 5 Drug Stocks With Fat Payouts Investopedia |
| Jun-17-18 06:30AM | Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma Business Wire |
| Jun-15-18 02:31PM | Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers Motley Fool |
| 08:32AM | China National Drug Administration Approves Countrys First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC) Business Wire |
| Jun-14-18 04:30PM | Bristol-Myers Squibb Announces Dividend Business Wire |
| Jun-13-18 06:00AM | Bristol-Myers Squibb to Present New Research Findings on the Treatment of Patients with Early Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018) Business Wire |
| Jun-12-18 05:32PM | Does Bristol-Myers Squibb Companys (NYSE:BMY) PE Ratio Signal A Selling Opportunity? Simply Wall St. |
| Jun-11-18 04:45PM | Bristol-Myers Squibb to Take Part in Goldman Sachs 39th Annual Global Healthcare Conference Business Wire |
| 09:29AM | Fred Hutch leases iconic Lake Union Steam Plant facility American City Business Journals |
| 09:08AM | The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie Zacks |
| Jun-08-18 10:27AM | Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant Zacks |
| Jun-07-18 09:09PM | Why Nektar Therapeutics Stock Stumbled 11.8% Today Motley Fool |
| 06:59AM | Bristol-Myers Squibb to Announce Results for Second Quarter 2018 on July 26 Business Wire |
| Jun-06-18 04:15PM | Here's Why Nektar Therapeutics Jumped as Much as 17% Today Motley Fool |
| 08:29AM | ASCO Ends: Winners & Losers at the Key Cancer Research Event Zacks |
| Jun-05-18 11:00AM | Nektar Therapeutics Stock Is a Buy After a Major Market Misread InvestorPlace |
| 08:42AM | Nektar (NKTR) and Bristol-Myers Present Data on Cancer Study Zacks |
| 08:13AM | Do Nektars disappointing clinical trial results invalidate $2 billion Bristol-Myers deal? MarketWatch |
| 06:08AM | Bristol-Myers (BMY) Reports Data from CheckMate-214 Study Zacks |
| Jun-04-18 05:14PM | Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug TheStreet.com |
| 04:40PM | Is Nektar Therapeutics Stock a Bargain Now? Motley Fool |
| 03:56PM | $15 billion biotech stock loses more than 40% of its value after skin cancer drug study falls short CNBC |
| 03:32PM | Merck emerges as key winner at ASCO conference CNBC Videos |
|
|
|
|
| Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a collaboration agreement with Nektar Therapeutics, Illumina, Inc., Janssen Pharmaceuticals, Inc., and Advantagene, Inc., as well as Tsinghua University. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Gordon Murdo | EVP, Chief Commercial Officer | Aug 01 | Option Exercise | 0.00 | 1,510 | 0 | 50,168 | Aug 03 05:05 PM | | Biondi Paul | SVP, Head of Strategy & BD | Jul 01 | Option Exercise | 0.00 | 1,461 | 0 | 1,461 | Jul 03 09:24 PM | | Caforio Giovanni | Chairman and CEO | May 05 | Option Exercise | 0.00 | 8,040 | 0 | 292,822 | May 08 05:05 PM | | Paliwal Dinesh C | Director | Apr 30 | Buy | 52.40 | 4,770 | 249,948 | 8,027 | May 02 04:05 PM | | Lynch Thomas J. Jr. | EVP & Chief Scientific Officer | Apr 03 | Option Exercise | 0.00 | 12,367 | 0 | 18,267 | Apr 05 04:37 PM | | Schmukler Louis S | Pres., Global Mfg. & Supply | Mar 10 | Option Exercise | 0.00 | 34,681 | 0 | 53,132 | Mar 13 04:57 PM | | Santiago Karen Murphy | Controller | Mar 10 | Option Exercise | 0.00 | 4,407 | 0 | 4,456 | Mar 13 04:55 PM | | JUDGE ANN POWELL | SVP, Global Human Resources | Mar 10 | Option Exercise | 0.00 | 36,044 | 0 | 75,370 | Mar 13 04:56 PM | | von Autenried Paul | SVP, Enterp. Services & CIO | Mar 10 | Option Exercise | 0.00 | 31,275 | 0 | 136,441 | Mar 13 04:54 PM | | Elicker John E | SVP, Public Affairs & IR | Mar 10 | Option Exercise | 0.00 | 20,043 | 0 | 86,932 | Mar 13 04:56 PM | | Caforio Giovanni | Chairman and CEO | Mar 10 | Option Exercise | 0.00 | 219,211 | 0 | 333,970 | Mar 13 04:56 PM | | Gordon Murdo | EVP, Chief Commercial Officer | Mar 10 | Option Exercise | 0.00 | 39,235 | 0 | 62,028 | Mar 13 04:55 PM | | Bancroft Charles A | EVP & Chief Financial Officer | Mar 10 | Option Exercise | 0.00 | 91,318 | 0 | 363,739 | Mar 13 04:53 PM | | LEUNG SANDRA | EVP, General Counsel | Mar 10 | Option Exercise | 0.00 | 68,896 | 0 | 488,677 | Mar 13 04:54 PM | | Bancroft Charles A | EVP & Chief Financial Officer | Feb 23 | Option Exercise | 22.14 | 37,460 | 829,364 | 302,348 | Feb 27 04:45 PM | | Samuels Theodore R. II | Director | Dec 15 | Buy | 62.30 | 4,000 | 249,187 | 22,000 | Dec 18 04:21 PM | | Lynch Thomas J. Jr. | EVP & Chief Scientific Officer | Dec 12 | Sale | 63.24 | 5,300 | 335,172 | 9,251 | Dec 13 05:31 PM | | LEUNG SANDRA | EVP, General Counsel | Dec 04 | Option Exercise | 22.14 | 156,582 | 3,466,725 | 584,373 | Dec 05 06:15 PM | | LEUNG SANDRA | EVP, General Counsel | Dec 04 | Sale | 63.37 | 156,582 | 9,922,601 | 427,791 | Dec 05 06:15 PM | | Bancroft Charles A | EVP & Chief Financial Officer | Dec 02 | Option Exercise | 0.00 | 6,401 | 0 | 267,770 | Dec 05 06:15 PM | | Elicker John E | SVP, Public Affairs & IR | Nov 01 | Option Exercise | 0.00 | 494 | 0 | 68,166 | Nov 03 04:32 PM | | Caldarella Joseph C | SVP & Controller | Sep 06 | Sale | 60.00 | 9,340 | 560,400 | 46,297 | Sep 08 04:31 PM | | Nielsen Anne | Chief Compliance & Ethics Off | Sep 03 | Option Exercise | 0.00 | 1,594 | 0 | 38,811 | Sep 06 04:46 PM |
|
|
|
|
|
|
